We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceuti...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a s...
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers...
Gilead Sciences, Inc. is a research-based bioph...
OraSure Technologies is empowering the global community to improve health and well...
OraSure Technologies is empowering the global c...
LeMaitre Vascular is a leading global innovator, manufacturer and marketer of devi...
LeMaitre Vascular is a leading global innovator...
InSitu Biologics is an emerging biotech company focusing on development of AnestaG...
InSitu Biologics is an emerging biotech company...
Join the National Investor Network and get the latest information with your interests in mind.